Clostridioides difficile Infection — Diagnosis and Targeted Treatment
Diagnose Clostridioides difficile infection using a two-step algorithm: stool GDH screening followed by toxin EIA, with NAAT reserved for discordant results (GDH-positive, toxin-negative). Classify severity as non-severe (WBC <15,000/mcL, creatinine <1.5 mg/dL), severe (WBC ≥15,000 or creatinine ≥1.5), or fulminant (hypotension, ileus, or megacolon). Treat initial non-severe and severe episodes with fidaxomicin 200 mg PO BID for 10 days as the preferred first-line agent, reserving oral vancomycin 125 mg PO QID for 10 days as the alternative. For fulminant disease, escalate to vancomycin 500 mg PO/NG QID plus metronidazole 500 mg IV q8h. Monitor clinical response at 48–72 hours using stool frequency trends and systemic markers — never repeat stool testing for cure. Recurrence occurs in 15–35% of patients within 8 weeks; manage first recurrence with extended-pulsed fidaxomicin and refer multiply recurrent cases for fecal microbiota transplant.
Pathophysiology
Clostridioides difficile infection is a toxin-mediated disease in which disruption of the normal colonic microbiome allows ingested C. difficile spores to germinate, colonize the large intestine, and produce two primary exotoxins — toxin A (TcdA, an enterotoxin) and toxin B (TcdB, a cytotoxin) — that directly damage colonic epithelial cells and trigger a robust inflammatory response culminating in pseudomembranous colitis. The pathogenesis begins when broad-spectrum antibiotic exposure eradicates protective anaerobic commensals, particularly Bacteroidetes and Firmicutes phyla, creating an ecological niche that permits C. difficile vegetative growth. The organism produces spores that are resistant to gastric acid, alcohol-based sanitizers, and standard environmental cleaning, enabling efficient healthcare-associated transmission.
- Core Mechanism
- Toxin B (TcdB) glucosylates Rho-family GTPases (RhoA, Rac1, Cdc42), inactivating cytoskeletal regulation and causing epithelial cell rounding, tight junction disruption, and apoptosis. Toxin A (TcdA) activates enteric sensory neurons and mast cells, amplifying fluid secretion and neutrophil recruitment.
- Key Pathway
- TcdB → Rho GTPase inactivation → actin cytoskeleton collapse → tight junction disruption → epithelial barrier failure → neutrophilic infiltration → pseudomembrane formation (fibrin + mucus + neutrophil debris + necrotic epithelium)
- Genetic Factors
- NAP1/BI/027 hypervirulent ribotype produces 16–23-fold more toxin A and toxin B due to mutations in the tcdC negative regulator gene; also produces binary toxin CDT (ADP-ribosyltransferase) that enhances adherence via microtubule protrusion formation
- Risk Factors
- MODIFIABLE: antibiotic exposure (fluoroquinolones, clindamycin, third-generation cephalosporins, carbapenems), PPI use (OR 1.3–2.0), prolonged hospitalization (>7 days) | NON-MODIFIABLE: age ≥65 (OR 2.5), immunosuppression (chemotherapy, transplant), inflammatory bowel disease, prior CDI episode
- Biomarkers
- Stool toxin A/B (diagnostic), fecal lactoferrin >7.25 mcg/mL (inflammatory marker), serum lactate >2.2 mmol/L (perfusion compromise in fulminant disease), WBC ≥15,000/mcL and creatinine ≥1.5 mg/dL (severity markers), serum albumin <2.5 g/dL (poor prognosis)
The disease progresses through a defined cascade: antibiotic-induced dysbiosis depletes colonization resistance → C. difficile spores germinate in response to primary bile acids (taurocholate) in the small intestine → vegetative cells colonize the cecum and colon → toxin production begins within 24–48 hours → TcdA binds to glycoprotein receptor gp96 on colonocytes triggering chloride secretion and fluid loss → TcdB penetrates the epithelial barrier and activates submucosal macrophages, mast cells, and dendritic cells via inflammasome-dependent IL-1-beta and IL-18 release → massive neutrophil recruitment forms the characteristic volcano-like pseudomembranous exudate visible on colonoscopy. In fulminant disease, transmural inflammation leads to colonic dilation (toxic megacolon ≥6 cm), ileus, bowel perforation, and septic shock. The spore-forming capacity of C. difficile ensures environmental persistence for months on hospital surfaces, bed rails, and shared equipment, driving the cycle of nosocomial transmission.
Diagnostic Protocol
Test only patients with clinically significant diarrhea — defined as three or more unformed stools within 24 hours — who have relevant risk factors such as recent antibiotic exposure, hospitalization, or age ≥65. Do not test formed stool. Do not send stool specimens from patients receiving laxatives unless CDI is strongly suspected and laxatives can be discontinued for 48 hours. Never repeat testing within 7 days of a negative result, and never perform test-of-cure after treatment completion. The preferred diagnostic approach is a multi-step algorithm that combines high-sensitivity screening with a confirmatory toxin assay, which balances detection sensitivity against clinical specificity for toxin-producing disease requiring treatment.
Severity Classification
| Severity | Criteria | Clinical Features | Treatment Approach |
|---|---|---|---|
| Non-Severe | WBC <15,000/mcL AND Cr <1.5 mg/dL | Watery diarrhea, mild abdominal cramping, low-grade fever | Fidaxomicin 200 mg PO BID or vancomycin 125 mg PO QID × 10 days |
| Severe | WBC ≥15,000/mcL OR Cr ≥1.5 mg/dL (or >50% above baseline) | Profuse diarrhea, abdominal distension, fever ≥38.5°C, hypoalbuminemia <3.0 g/dL | Vancomycin 125 mg PO QID × 10 days or fidaxomicin 200 mg PO BID × 10 days |
| Fulminant | Hypotension, ileus, toxic megacolon (≥6 cm), or ICU admission | Absent stool output (ileus), peritoneal signs, shock, lactate ≥2.2 mmol/L, multi-organ dysfunction | Vancomycin 500 mg PO/NG QID + metronidazole 500 mg IV q8h ± vancomycin retention enema |
Diagnostic Workup
| Test | Rationale / What It Shows | Sensitivity | Specificity |
|---|---|---|---|
| GDH Antigen (Step 1 screen) | Detects glutamate dehydrogenase common to all C. difficile strains (toxigenic and non-toxigenic); rapid turnaround 30–60 min | 85–100% | 87–98% |
| Toxin A/B EIA (Step 2 confirmatory) | Detects free toxins A and B in stool; confirms active toxin-producing disease; specificity advantage over NAAT | 55–85% | 95–99% |
| NAAT / PCR (arbiter for discordant) | Detects tcdB gene; used when GDH positive but toxin EIA negative (discordant result) to differentiate colonization from low-level toxin production | 95–99% | 85–95% |
| Stool lactoferrin / calprotectin | Fecal inflammation marker; lactoferrin >7.25 mcg/mL supports inflammatory diarrhea; helps distinguish CDI from non-inflammatory etiologies | 78–92% | 60–80% |
| CT abdomen/pelvis | Colonic wall thickening (>4 mm), pericolonic stranding, ascites, colonic dilation ≥6 cm (megacolon); reserve for suspected complications | 52–85% | 90–95% |
Differential Diagnosis
| Condition | Distinguishing Feature | Key Workup |
|---|---|---|
| Antibiotic-associated diarrhea (non-CDI) | Osmotic mechanism without colonic inflammation; stools are watery but non-bloody; WBC normal; resolves within 48–72 hours of antibiotic cessation | Stool C. difficile testing negative; fecal lactoferrin negative |
| Inflammatory bowel disease flare | Chronic relapsing course with bloody diarrhea, extraintestinal manifestations (arthralgia, uveitis, erythema nodosum); continuous mucosal inflammation on endoscopy (UC) or skip lesions (Crohn) | Fecal calprotectin >250 mcg/g; colonoscopy with biopsy; rule out concurrent CDI (10–15% overlap) |
| Ischemic colitis | Sudden onset crampy left-sided abdominal pain with bloody diarrhea in elderly or vascular disease patients; watershed distribution (splenic flexure) | CT angiography; colonoscopy showing single-stripe sign; lactate elevation if advanced |
| Norovirus gastroenteritis | Sudden onset vomiting and watery diarrhea with 24–72 hour self-limited course; outbreak setting; no significant leukocytosis or colonic wall thickening | Norovirus PCR stool panel; supportive care only |
| Medication-induced diarrhea (non-antibiotic) | Temporal association with offending agent (metformin, colchicine, SSRIs, magnesium-containing antacids); dose-dependent; resolves with dose reduction or discontinuation | Medication reconciliation; stool studies negative; osmotic gap may be elevated |
Severity classification
Initial C. difficile episode in adults: severity and treatment
Non-severe and severe episodes take the same oral regimen; fulminant disease needs an escalated one.
Non-severe
- WBC <15,000/mcL AND creatinine <1.5 mg/dL
Management
- Fidaxomicin 200 mg PO BID × 10 days (preferred)
- Alternative: vancomycin 125 mg PO QID × 10 days
Severe
- WBC ≥15,000/mcL OR creatinine ≥1.5 mg/dL
Management
- Same as non-severe: fidaxomicin 200 mg PO BID × 10 days (preferred)
- Alternative: vancomycin 125 mg PO QID × 10 days
Fulminant
- Hypotension, ileus, or megacolon
Management
- Vancomycin 500 mg PO/NG QID plus metronidazole 500 mg IV q8h
- If ileus, consider adding vancomycin 500 mg in 100 mL NS retention enema QID
Every class: stop the offending antibiotic whenever clinically feasible.
Every fulminant case: emergent surgical/ICU consultation.
Treatment Algorithm
The primary goals of CDI treatment are to eradicate the active infection, restore colonic microbiome diversity, and prevent recurrence. Discontinue the offending antibiotic immediately whenever clinically feasible — this single intervention reduces symptom duration by 24–48 hours. Avoid antimotility agents (loperamide) in active CDI as they may mask symptom improvement and theoretically increase toxin contact time with the colonic mucosa. Empiric CDI therapy should begin immediately upon clinical suspicion in moderate-to-severe presentations while awaiting laboratory confirmation; do not delay treatment for test results in critically ill patients. Fidaxomicin has supplanted metronidazole entirely and is now preferred over vancomycin for both initial and recurrent episodes based on superior sustained clinical response and lower recurrence rates.
For all initial CDI episodes regardless of severity classification, fidaxomicin is the preferred first-line agent. It achieves clinical cure rates of 88–92% with a significantly lower 30-day recurrence rate compared to vancomycin (13% vs. 27%). Grade A Oral vancomycin remains an acceptable alternative when fidaxomicin is unavailable or cost-prohibitive. Metronidazole is no longer recommended for initial treatment of any severity tier.
Fidaxomicin (Dificid): Fidaxomicin 200 mg PO BID × 10 days
Vancomycin (Vancocin) oral: Vancomycin 125 mg PO QID × 10 days
Fulminant CDI requires aggressive combination therapy. High-dose oral/nasogastric vancomycin provides direct intraluminal delivery of drug to the colon, while intravenous metronidazole achieves colonic tissue concentrations through biliary excretion. When ileus is present, rectal vancomycin ensures drug delivery to the distal colon. Grade B Obtain urgent surgical consultation for all fulminant cases — subtotal colectomy is the definitive rescue intervention when medical therapy fails.
Vancomycin high-dose oral: Vancomycin 500 mg PO/NG QID
Metronidazole IV: Metronidazole 500 mg IV q8h
Vancomycin rectal (if ileus): Vancomycin 500 mg in 100 mL NS retention enema QID
Recurrence occurs in 15–35% of patients after a first episode, with risk increasing to 40–65% after a second episode. For first recurrence, extended-pulsed fidaxomicin is the preferred regimen based on the EXTEND trial, reducing subsequent recurrence by approximately 50% compared to standard-duration vancomycin. Grade A For multiply recurrent CDI (second or subsequent recurrence), fecal microbiota transplant (FMT) achieves cure rates of 85–90%. Bezlotoxumab, a monoclonal antibody targeting toxin B, is an adjunctive strategy given as a single infusion during antibiotic treatment to reduce recurrence risk.
First recurrence — Fidaxomicin extended-pulsed: Fidaxomicin 200 mg PO BID × 10 days, then 200 mg PO once daily every other day × 20 days
Alternative first recurrence — Vancomycin taper-pulse: Vancomycin 125 mg PO QID × 10–14 days, then 125 mg BID × 7 days, then 125 mg daily × 7 days, then 125 mg every 2–3 days × 2–8 weeks
Bezlotoxumab (Zinplava) adjunct: Bezlotoxumab 10 mg/kg IV single infusion during CDI antibiotic treatment
FMT (multiply recurrent): Fecal microbiota transplant via colonoscopy, enema, or approved oral product after vancomycin washout
Special Populations
| Population | Drug / Consideration | Specific Recommendation |
|---|---|---|
| Renal Impairment | Vancomycin oral / Fidaxomicin | No dose adjustment needed for oral vancomycin (minimal systemic absorption from intact GI tract). Fidaxomicin requires no renal adjustment (fecal elimination >92%). IV metronidazole: standard dosing for CrCl >10 mL/min; accumulates in dialysis patients — dose after HD sessions. |
| Hepatic Impairment | Metronidazole / Fidaxomicin | Reduce metronidazole dose by 50% in Child-Pugh C cirrhosis (hepatic metabolism, prolonged half-life >20 hours). Fidaxomicin: no hepatic dose adjustment required. Oral vancomycin: no adjustment needed. Monitor for metronidazole-related hepatotoxicity (transaminases q72h). |
| Elderly (≥65) | All CDI agents | Age ≥65 is an independent risk factor for CDI recurrence (OR 2.5) and severe disease. Prefer fidaxomicin over vancomycin for initial episodes given the critical importance of preventing recurrence in this population. Consider bezlotoxumab 10 mg/kg IV co-administration for patients ≥65 with any recurrence risk factor. Monitor renal function closely if using IV metronidazole. |
| Pregnancy | Vancomycin oral / Metronidazole | Oral vancomycin is the preferred agent in pregnancy (negligible systemic absorption, no teratogenic signal). Metronidazole: historically avoided in first trimester due to theoretical mutagenicity, though recent meta-analyses show no increased birth defect risk. Fidaxomicin: limited human pregnancy data; use only if benefit outweighs risk. FMT: insufficient safety data in pregnancy. |
| Pediatric | Vancomycin oral / Metronidazole | Children <2 years: do NOT test for C. difficile (high asymptomatic carriage rate 37–70%). Ages 2–17: vancomycin 10 mg/kg PO QID (max 125 mg/dose) × 10 days for non-severe/severe. Metronidazole 7.5 mg/kg PO TID (max 500 mg/dose) × 10 days as alternative for non-severe only. Fidaxomicin: FDA-approved for ages ≥6 months; dosing 16 mg/kg BID (max 200 mg) oral suspension. |
| Immunocompromised | Fidaxomicin / Bezlotoxumab | Solid organ transplant, active chemotherapy, and chronic immunosuppression increase CDI severity and recurrence risk (OR 3–5). Strongly prefer fidaxomicin for initial episodes. Add bezlotoxumab 10 mg/kg IV for any episode in this population. FMT carries theoretical risk of pathogen transmission in immunosuppressed patients; use FDA-approved microbiota products with donor screening when possible. |
Drug Interactions
| Drug | Interacting Agent | Mechanism | Clinical Effect | Management |
|---|---|---|---|---|
| Metronidazole | Alcohol (ethanol) | Inhibits aldehyde dehydrogenase, causing acetaldehyde accumulation | Disulfiram-like reaction: flushing, nausea, vomiting, tachycardia, hypotension | Strict alcohol avoidance during treatment and for 72 hours after last dose. Includes alcohol-containing medications and mouthwash. |
| Metronidazole | Warfarin | Inhibits CYP2C9-mediated S-warfarin metabolism | Potentiated anticoagulation, INR elevation 2–3-fold, increased bleeding risk | Check INR within 3 days of starting metronidazole. Reduce warfarin dose by 25–50% empirically. Monitor INR every 2–3 days during co-administration. |
| Fidaxomicin | Cyclosporine (P-gp inhibitor) | Cyclosporine inhibits P-glycoprotein efflux pump, increasing fidaxomicin systemic absorption | 2-fold increase in fidaxomicin plasma concentrations (though systemic levels remain very low due to minimal baseline absorption) | No dose adjustment required per manufacturer labeling. Fidaxomicin efficacy is driven by intraluminal concentrations, not systemic levels. Monitor for GI side effects. |
| Vancomycin oral | Cholestyramine / bile acid sequestrants | Cholestyramine binds vancomycin in the GI lumen, reducing intraluminal drug concentration | Decreased vancomycin efficacy against C. difficile; subtherapeutic fecal drug levels | Separate administration by at least 2 hours. Alternatively, consider fidaxomicin which is not bound by bile acid sequestrants. |
| Bezlotoxumab | No significant drug interactions | Monoclonal antibody cleared by proteolytic catabolism; does not interact with CYP enzymes or transporters | None clinically significant | No dose adjustment needed with any concurrent medication. Infuse over 60 minutes. Monitor for infusion reactions. |
C. difficile infection is a bacterial infection of the large intestine that usually occurs after taking antibiotics. The antibiotics disrupt the healthy bacteria in your gut, allowing C. difficile bacteria to grow and release toxins that cause inflammation and diarrhea. Your doctor diagnoses this with a stool test. Treatment is with a specific oral antibiotic (fidaxomicin or vancomycin) taken for 10 days. Most people improve within 2–3 days. However, about 1 in 4 patients may experience a relapse within 8 weeks. If this happens, your doctor may use a longer antibiotic course or a procedure called fecal microbiota transplant to restore healthy gut bacteria.
Monitoring & Surveillance
Monitor clinical response based on symptom trajectory, not stool testing. The primary endpoint is reduction in diarrheal episodes from baseline — expect improvement in stool frequency, abdominal cramping, and systemic signs (fever, leukocytosis) within 48–72 hours of initiating appropriate antibiotic therapy. Do not repeat stool C. difficile testing for cure: toxin EIA and NAAT can remain positive for weeks to months after successful treatment due to persistent organism shedding. Track laboratory markers of severity (WBC, creatinine, lactate, albumin) daily in hospitalized patients and every 48–72 hours in outpatients. Recurrence surveillance extends for 8–12 weeks after treatment completion, with highest risk in the first 2–4 weeks. Educate patients on recurrence warning signs: return of watery diarrhea (≥3 unformed stools/day), abdominal pain, and fever within 8 weeks of completing treatment.
- CBC with differential (WBC, absolute neutrophil count)
- BMP: creatinine, BUN, electrolytes
- Serum albumin (prognostic marker)
- Serum lactate (if severe/fulminant suspected)
- Stool frequency log (number of unformed stools/24h)
- Stool frequency trend (expect ≥20% reduction)
- Temperature curve (fever resolution)
- WBC and creatinine reassessment
- Clinical reassessment: if no improvement, escalate therapy or reassess severity
- Confirm clinical cure: formed stools or ≤2 unformed stools/day
- No repeat stool testing (test-of-cure not recommended)
- Educate on recurrence signs and when to seek care
- Surveillance for recurrence (15–35% risk within 8 weeks)
- New-onset diarrhea (≥3 unformed stools/day): re-test with same algorithm
- Assess ongoing antibiotic stewardship and PPI de-prescribing
Response & Safety Parameters
| Parameter | Target / Threshold | Frequency | Action if Abnormal |
|---|---|---|---|
| Stool frequency | ≥20% reduction from baseline by 72 hours; ≤3 unformed stools/day by day 5–7 | Daily stool count log | If no improvement by 72 hours: reassess severity, consider CT abdomen, escalate therapy or switch regimen |
| WBC count | Trending downward toward <15,000/mcL | q24–48h (inpatient) | Rising WBC >20,000 or >25,000: reclassify as severe/fulminant, surgical consultation, intensify treatment |
| Serum creatinine | Trending toward baseline (<1.5 mg/dL or <50% above pre-illness value) | q24–48h (inpatient) | Rising creatinine: aggressive IV fluid resuscitation, reassess severity, consider nephrotoxic drug review |
| Serum lactate | <2.0 mmol/L (fulminant cases only) | q6–12h in fulminant disease | Lactate ≥5.0 mmol/L or rising despite 24h therapy: emergent surgical consultation for subtotal colectomy |
| Abdominal imaging | No colonic dilation ≥6 cm; no free air | CT at presentation for severe/fulminant; repeat if clinical deterioration | Megacolon (≥6 cm), free air, or perforation: emergent surgical intervention |
Clinical Commentary
Infectious disease consultation: Any patient with a second or subsequent CDI recurrence despite appropriate antibiotic therapy, immunocompromised patients with severe CDI, patients failing fidaxomicin or vancomycin taper-and-pulse, or cases where FMT is being considered.
FMT center referral: After the second recurrence (third total episode), refer to a center offering fecal microbiota transplant. Both conventional donor-stool FMT and FDA-approved microbiota products (Vowst, Rebyota) are options. Patients should complete a vancomycin washout course (125 mg PO QID for at least 3 days, with last dose 24–48 hours before FMT) to reduce C. difficile burden before microbiome restoration.
- Optimal duration and dosing of the fidaxomicin extended-pulsed regimen for first recurrence remains under investigation; the EXTEND trial protocol is the current standard but alternatives are being studied
- The role of bezlotoxumab in combination with FMT for multiply recurrent CDI lacks randomized trial data; some clinicians use both, but the incremental benefit is uncertain
- Whether proton pump inhibitor de-prescribing after CDI diagnosis actually reduces recurrence risk causally (vs. the epidemiologic association) remains debated
- Long-term safety and durability of FDA-approved microbiota products (Vowst, Rebyota) beyond 8-week follow-up periods in pivotal trials are still being characterized through post-marketing surveillance
Practice Insights: Lessons From the Bedside
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Across infectious disease and inpatient medicine services, Clostridioides difficile infection is the field where the IDSA 2021 guideline shift toward fidaxomicin as first-line agent — and the simultaneous availability of live biotherapeutic products SER-109 and RBX2660 for recurrence prevention — has fundamentally rewritten the modern management algorithm away from sequential vancomycin courses toward outcome-targeted upfront therapy with adjunctive prevention.
What the Guideline Misses
Fidaxomicin (200 mg twice daily for 10 days) is now preferred first-line over oral vancomycin per IDSA/SHEA 2021 update, based on lower recurrence rates (~15% versus ~25% with vancomycin). The reflexive vancomycin prescription that anchored older practice misses the recurrence-reduction benefit that fidaxomicin’s narrower spectrum and microbiome-sparing properties produce. Cost remains a barrier in some settings, but the avoided second course and recurrence-care utilization typically offsets the upfront drug cost.
Patterns That Recur
NAAT-only testing (without confirmatory toxin EIA) over-diagnoses C. difficile by detecting toxigenic strains in patients who are colonized but not infected. The 2021 guidelines explicitly recommend two-step testing: either GDH + toxin EIA (or NAAT + toxin EIA) to distinguish active infection from colonization. Laboratory protocols should mandate this two-step approach, and the over-diagnosis pattern seen where NAAT-only testing remained in use produced substantial inappropriate antibiotic exposure and isolation.
A Bedside Heuristic
Discontinue the offending antibiotic when clinically possible, discontinue proton pump inhibitors not strictly indicated, soap-and-water hand hygiene (alcohol-based gels do NOT kill C. difficile spores), and single-patient room with contact precautions are non-negotiable bundle elements. The lifestyle and infection control measures parallel the pharmacologic treatment and produce a substantial fraction of the cure in many cases.
The Recurrence Doctrine
Bezlotoxumab (anti-toxin B monoclonal antibody, single infusion 10 mg/kg) for adjunctive recurrence prevention in high-risk patients — age over 65, severe disease, immunocompromise, prior C. difficile infection. Live biotherapeutic products (SER-109 or RBX2660) for recurrence after the first or second episode, with traditional fecal microbiota transplantation (FMT) via colonoscopy reserved for refractory cases or where the regulated live biotherapeutics are unavailable. The shift from FMT-as-last-resort to FMT-as-second-recurrence has happened over the past 5 years.
Illustrative Scenario
A woman in her late seventies developed diarrhea and abdominal pain on hospital day 8 following completion of a 7-day course of ceftriaxone for community-acquired pneumonia. Stool studies were positive for both GDH antigen and toxin EIA (true infection rather than colonization), with WBC 18,400, creatinine 1.6 mg/dL up from 0.9 baseline, and albumin 2.8. Severity criteria met for severe C. difficile infection. She was placed in single-patient isolation with contact precautions, ceftriaxone was already completed, her chronic omeprazole was discontinued, and fidaxomicin 200 mg orally twice daily for 10 days was initiated. Given her age over 65 plus severe disease, bezlotoxumab 10 mg/kg IV was administered on hospital day 2 as adjunctive recurrence prevention. Diarrhea resolved by day 6 of therapy, and she was discharged on hospital day 10 having completed the fidaxomicin course. At week 6 post-discharge, she presented with recurrent diarrhea and stool retesting again positive — a recurrence despite bezlotoxumab. Fidaxomicin was restarted (extended-pulsed regimen: standard dosing for 5 days, then every other day for 20 days), and colonoscopic fecal microbiota transplantation was arranged 2 weeks after symptom resolution. At 12 months post-FMT she remained recurrence-free.
Protocol Adjustments to the Standard Pathway
- Two-step testing algorithm — GDH + toxin EIA, or NAAT + toxin EIA — rather than NAAT-only testing. The two-step approach distinguishes active infection from colonization, reducing inappropriate antibiotic exposure and isolation.
- Fidaxomicin 200 mg PO BID × 10 days as first-line per IDSA/SHEA 2021, based on lower recurrence rates. Oral vancomycin 125 mg QID × 10 days as alternative when cost or formulary access limits fidaxomicin.
- Bezlotoxumab (10 mg/kg IV single dose) for recurrence prevention in high-risk patients — age over 65, severe disease, immunocompromise, prior C. difficile infection. Administered during the index treatment course.
- FMT or live biotherapeutic products (SER-109, RBX2660) for ≥2 recurrences, rather than indefinite sequential antibiotic courses. The shift from FMT-as-last-resort to FMT-after-second-recurrence reflects regulatory approval and outcome data over the past 5 years.
Frequently Asked Questions
- Clostridioides difficile Infection: Diagnosis, Risk Stratification, and Fidaxomicin-First Treatment
- Clostridioides difficile Infection: Vancomycin and Fidaxomicin Treatment, FMT for Recurrent Disease
- Urinary Tract Infection Diagnosis and Management: A Comprehensive Clinical Guideline
- Whipple Disease: Diagnosis, Antibiotic Treatment, and Long-Term Management
- Pneumocystis Jirovecii Pneumonia: Diagnosis, Treatment, and Prophylaxis
- Syphilis: Diagnosis, Staging, and Treatment Management
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- IDSA/SHEA 2021 focused update: Clostridioides difficile infection (Clinical Infectious Diseases · 2021)